CTOs on the Move

MedPharm

www.medpharm.com

 
MedPharm is a world-leading contract provider of topical and transdermal product design and development services. Our delivery of robust and innovative research has commanded recognition from regulators and investors alike. We utilise our unique cost-effective performance testing models to mitigate risk and accelerate development times.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.medpharm.com
  • 4222 Emperor Boulevard Suite 335
    Durham, NC USA 27703
  • Phone: 919.436.4985

Executives

Name Title Contact Details
Dave Haas
Vice President Information Technology Profile
Jon Lenn
Chief Technology Officer and Chief Scientific Officer Profile

Similar Companies

DaVita Rx

DaVita RxⓇ is the first and largest full-service pharmacy created specifically for the unique needs of kidney patients, and has expanded to other complex conditions as well. We make it easier for patients to get their medications and follow their drug regimens. We give providers a whole new way to improve patient care.

North Bend Medical Center

NBMC is a multi-specialty, regional medical center with more than 400 employees and 70 medical providers representing approximately 20 specialties

TearClear

TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development.

Xerimis Inc

Xerimis Inc is a Moorestown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.